Is a complete TXG research report available?

No complete published report is available for 10x Genomics, Inc. (TXG) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

10x Genomics, Inc. (TXG)

NASDAQ: TXG · USD

$47.1

+1.13 (+2.5%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-29 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first TXG analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	6B
Revenue (ttm)	638.8M
Net income (ttm)	-22.7M
EPS (ttm)	-$0.18
Shares out	127M
Volume	2,563,234
Beta	2.04
Price target	$41.5	-11.7%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 638.8M
Net income (ttm): -22.7M
EPS (ttm): -$0.18
Market cap: 6B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All TXG indicators

Market & fundamental data

Available fields

236

Groups with data

Currency

USD

Showing 236 of 236 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001770787
Company name	10x Genomics, Inc.
Country	United States
Country code	US
Cusip	88025U109
Employees	1,178
Employees Change	-128%
Employees Change Percent	-9.8
Enterprise value	$5.5B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Health Information Services
Industry PE Fwd	29.78
IPO Date	2019-09-12
Isin	US88025U1097
Last refreshed	2026-07-29
Market cap	$6B
Market cap category	Mid-Cap
Price	$47.05
Price currency	USD
Rev Per Employee	542,260.61x
Sector	Healthcare
Sector PE	45.6
Sector PE Fwd	24.3
Sic	3826
Symbol	TXG
Website	https://www.10xgenomics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-0.38%
EV Sales Forward	8.85x
EV/EBITDA	764.99x
EV/FCF	45.14x
EV/Sales	8.63x
FCF yield	2.05%
P/B ratio	7.45x
P/S ratio	9.35x
PS Forward	9.58x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-6.06%
EBITDA Margin	1.13%
FCF margin	19.13%
Gross margin	69.68%
Gross Profit	$445.1M
Gross Profit Growth	4.31%
Gross Profit Growth Q	0.7%
Gross Profit Growth3 Y	3.14%
Gross Profit Growth5 Y	10.68%
Net Income	$-22.7M
Net Income Growth Quarters	5%
Net Income Growth Years	2%
Pretax Margin	-3.01%
Profit Margin	-3.55%
Profit Per Employee	$-19,233
ROA	-4.48
Roa5y	-9.03
ROCE	-4.29
ROE	-2.98
Roe5y	-18.37
ROIC	-5.11

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	233.73%
Cagr3y	-8.14%
Cagr5y	-23.52%
EPS Growth Quarters	5
EPS Growth Years	2
FCF Growth	169.33%
FCF Growth Q	-24.45%
OCF Growth	125.27%
OCF Growth Q	-23.96%
Revenue Growth	2.26x
Revenue Growth Q	-2.61x
Revenue Growth Years	1x
Revenue Growth3 Y	6.01x
Revenue Growth5 Y	13.93x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.67
Assets	$1B
Cash	$539.8M
Current Assets	$669.7M
Current Liabilities	$113.6M
Debt	$81.4M
Debt EBITDA	$11.29
Debt Equity	$0.1
Debt FCF	$0.67
Equity	$814.3M
Liabilities	$201.4M
Long Term Assets	$346M
Long Term Liabilities	$87.8M
Net Cash	$458.5M
Net Cash By Market Cap	$7.68
Net Cash Growth	32.19%
Net Debt EBITDA	$-63.6
Net Debt Equity	$-0.56
Net Debt FCF	$-3.75
Tangible Book Value	$749.9M
Tangible Book Value Per Share	$5.81
WACC	15.28

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.9
Inventory Turnover	3.02
Net Working Capital	$27.6M
Quick ratio	5.25
Working Capital	$556.1M
Working Capital Turnover	$1.24

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-4.06%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	233.45%
200-day SMA	22.81
3Y total return	-22.5%
50-day SMA	35.02
50-day SMA vs 200-day SMA	50over200
5Y total return	-73.82%
All Time High	209
All Time High Change	-77.49%
All Time High Date	2021-06-29
All Time Low	6.78
All Time Low Change	593.95%
All Time Low Date	2025-04-07
ATR	2.7
Beta	2.04
Beta1y	1.31
Beta2y	1.52
Ch YTD	188.5
High	47.37
High52	49.5
High52 Date	2026-07-23
High52ch	-4.95%
Low	45.02
Low52	11.16
Low52 Date	2025-10-14
Low52ch	321.6%
Ma50ch	34.34%
Premarket Change Percent	0.17
Premarket Price	$46
Premarket Volume	1,108
Price vs 200-day SMA	106.23%
RSI	66.8
RSI Monthly	68.16
RSI Weekly	80.11
Sharpe ratio	2.02x
Sortino ratio	3.69
Total Return	-4.06%
Tr YTD	188.5
Tr1m	28.03%
Tr1w	-0.32%
Tr3m	111.18%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	16
Analyst Count Top	5
Analyst Price Target Top	$32.5
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.06
Earnings Revenue Estimate	146,678,880x
Earnings Revenue Estimate Growth	-15.17x
Operating Income	$-68.8M
Operating margin	-10.77
Price target	$41.54
Price Target Change	$-11.71
Price Target Change Top	$-30.92

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	114,792,202%
Float Percent	90.42%
Shares Insiders	8.03%
Shares Institutions	96.23%
Shares Out	126,956,189
Shares Qo Q	0.95%
Shares Yo Y	4.06%
Short Float	14.16%
Short Ratio	4.58
Short Shares	12.8

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$21.5M
Adjusted OCF	27,135,000
Average Volume	2,922,743.7x
Bv Per Share	6.31
CAPEX	$-5.6M
Ch1m	28.03
Ch1w	-0.32
Ch1y	233.5
Ch3m	111.2
Ch3y	-22.5
Ch5y	-73.82
Ch6m	117.6
Change	2.46%
Change From Open	2.46
Close	45.92
Days Gap	0
Depreciation Amortization	38,134,000
Dollar Volume	120,600,159.7
Earnings Date	2026-08-06
Earnings Time	amc
EBIT	$-38.7M
EBITDA	$7.2M
EPS	$-0.18
F Score	4
FCF	$122.2M
FCF EV Yield	2.22x
FCF Per Share	$0.96
Financing CF	-2,036,000
Fiscal Year End	December
Founded	2,012
Goodwill	4,511,000
Income Tax	$3.4M
Investing CF	-12,856,000
Ipr	20.64
Iprfo	-12.87
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-13
Ma150	25.34
Ma150ch	85.67%
Ma20	43.19
Ma20ch	8.93%
Net CF	113,224,000
Next Earnings Date	2026-08-06
Open	45.92
Optionable	Yes
P FCF Ratio	48.89
P FCF Ratio SBC	277.9
P OCF Ratio	46.73
P OCF Ratio SBC	220.1
Position In Range	86.38
Post Close	47.05
Postmarket Change Percent	0.96
Postmarket Price	$47.5
Ppne	278,981,000
Pre Close	45.92
Price Date	2026-07-28
Price EBITDA	$829
Ptbv Ratio	7.97
Relative Volume	0.88x
Revenue	638,783,000x
SBC By Revenue	15.76x
Share Based Comp	100,684,000
Tax By Revenue	0.53x
Tr6m	117.62%
Us State	California
Volume	2,563,234
Z Score	4.3

10x Genomics, Inc. (TXG)

Coverage state: Market snapshot only — no published research

Generate the first TXG analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · TXG

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All TXG indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on TXG

Frequently asked questions